Brighter - Q220 results
Brighter recently announced Q220 results. Not surprisingly, the COVID-19 pandemic has caused some commercialisation delays, especially with the registration of Actiste in the United Arab Emirates (UAE). However, as of May the service is commercially available in Sweden and the company is harvesting user insights that will help it improve the experience over time. Additionally, the company announced a partnership with the provincial government of West Java (population of c 50 million) in Indonesia for a pilot.Brighter publ AB is a Sweden-based company active in the healthcare sector. It is primarily engaged in the development of Brighter One, a self-care device dedicated for type 1 and type 2 diabetes patients. Brighter One integrates a lancet, blood glucose meter for test strips, dosing and injection mechanism, and storage of glucose level and dosing history data. The Company cooperates with partners such as Almi Foretagspartner AB and Innovationsbron, as well as a distributor Rubin Medical.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.